Journal
JOURNAL OF EMERGENCY MEDICINE
Volume 31, Issue 2, Pages 177-180Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jemermed.2005.08.020
Keywords
hMG-CoA reductase inhibitors; rhabdomyolysis; drug toxicity; hepatitis; hyperlipidemia; cyclosporine; simvastatin; drug interactions
Categories
Ask authors/readers for more resources
Simvastatin and other HMG-CoA reductase inhibitors (statins) are one of the most frequently prescribed class of medications in the United States, with over 15 million Americans taking these drugs. Relatively rare adverse effects related to the known toxic effects of these drugs are more common than generally realized. Clinically significant statin-induced rhabdomyolysis is an uncommon but life-threatening adverse effect. We describe a case of simvastatin-induced rhabdomyolysis. Current knowledge of the pharmacology of the HMG-CoA reductase inhibitors and the drug interactions that potentiate these adverse effects are discussed. The clinical features of rhabdomyolysis and current treatment recommendations are presented. (C) 2006 Elsevier Inc.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available